Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update

15.05.2023 - – Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) – – Strong prescription growth across three promoted products – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., May 15, ...

Related Keywords

Japan ,John Donofrio ,Brown Stafford ,Paula Brown Stafford ,Jenene Thomas ,Ligand Pharmaceuticals Inc ,Company Or Novan Nasdaq ,Exchange Commission On Form ,Company Nitricil ,Novan Inc ,Exchange Commission ,Sato Pharmaceutical Co Ltd ,Dermatology Research Development ,Drug Administration ,Chief Executive ,Financial Results ,First Quarter ,Ligand Pharmaceuticals ,Executive Vice President ,Chief Operating Officer ,New Drug ,Private Securities Litigation Reform ,Consolidated Statements ,Months Ended March ,Onovan ,